1LEE S D,KIM H J,HWANG S J,et al.Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine:a case report[J].The Korean J Intern Med,2007,22(2):109-112.
2LIN E,MORRIS J S,AYERS G D.Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumot activity[J].Oncology(Huntingt),2002,16(12):31-37.
3MILANO G,ETIENNE GRIMALDI M C,MARI M,et al.Candidate mechanisms for capecitabine-related hand-foot syndrome[J].Br J Clin Pharmacol,2008,66(1):88-95.
4HONDA J,SASA M,MORIYA T,et al.Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results[J].J Med Invest,2008,55(1-2):54-60.
5ASGARI M M,HAGGERTY J G,MCNIFFJ M,et al.Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors[J].J Cutan Pathol,1999,26(6):287-294.
6MROZEK ORLOWSKI M E,FRYE D K,SANBORN H M.Capecitabine:nursing implications of a new oral chemotherapeutic agent[J].Oncol Nurs Forum,1999,26(4):753-762.
7HESS V,SALZBERG M,BORNER M,et al.Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma:a phase Ⅰ/Ⅱ trial[J].J Clin Oncol,2003,21(1):66-68.
8BASTIDA J,DIAZ CASCAJO C,BORGHI S.Chemotherapy-induced acral erythema due to tegafur[J].Acta Derm Venereol,1997,77(1):72-73.
9PARK Y H,RYOO B Y,LEE H J,et al.High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy[J].Ann Oncol,2003,14(11):1691-1692.
10JANUSCH M,FISCHER M,MARSCH W C H,et al.The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy[J].Eur J Dermatol,2006,16(5):494-499.
4B1um JL,Jones SE,Buzdar AU,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel refractory metastatic breast cancer[J].J Clin Onco1,1999,17:485-493.
5Reichardt P,Von Mnckwitz G,Thuss-Patience PC,et al.Multicenter phase Ⅱ study of oral capecitabine(Xeloda)in patients with metastatic breast cancer relapsing after treatment with a taxanecontaining therapy[J].Ann Oncol,2003,14:1227-1233.
6Abushullaih S,Saad ED,Munsell M,et al.Incidence and severity of handfoot syndrome in colorectal cancer patients treated with capecitabine:a single-institution experience[J].Cancer Invest,2002,20:3-10.
5Chalermchai T, Tantiphlachiva K, Suwanrusme H, et al. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia [J]. Asia Pac J Clin Oncol, 2010, 6(3): 155-160.
6Mortimer JE, Lauman MK, Tan B, et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine[J]. J Oncol Pharm Pract, 2003, 9:161-166.
7Mrochen-Donfin I. Nowara E, Kaleta B. "Hand-foot" syndrome- after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)[J]. Ginekol Pol, 2008, 79 (5):332-337.
8Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy [J]. Cancer, 1995, 75(8): 2169-2173.
9Marlschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodyses-thesia[J]. Anticancer Res, 2009, 29(6): 2307-2313.
